Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences

Rhea-AI Summary

Mindset Pharma (OTCQB: MSSTF), a drug discovery company, announced important poster presentations for its psilocybin-like candidate, MSP-1014, at two upcoming scientific conferences. The presentations will occur at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit in Boston on October 31, 2022, and at Neuroscience 2022 in San Diego on November 13, 2022. Research highlights include preclinical safety and pharmacokinetics studies comparing MSP-1014 and psilocybin.

5^th Annual Neuropsychiatric & Psychedelics Drug Development Summit in Boston, MA on October 31^st

Neuroscience 2022 by the Society of Neuroscience in San Diego, CA on November 13^th

TORONTO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced upcoming poster presentations related to its second-generation psilocybin-like lead drug candidate, MSP-1014 at two upcoming scientific conferences.

The poster presentations compare a novel prodrug of psilocin, MSP-1014, to psilocybin in preclinical studies evaluating safety, behavioral and pharmacokinetics properties of both psilocin prodrugs. In addition, collaborative work will be presented on benchmarking psilocybin in various animal models.

5^th Annual Neuropsychiatric & Psychedelics Drug Development Summit
Location: Boston, MA
Titles: “The Preclinical Safety, Behavioral and Pharmacokinetics Properties of a Novel Prodrug of Psilocin, MSP-1014”; “Evaluation of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Properties of Psilocybin in Rodents”; and “Differential Effects of Psilocybin Across Two Pre-Clinical Assays in the Rat.”
Date/Time: Monday, October 31, 2022, at 3:15 p.m. ET
Presenter: Joseph Araujo, Chief Scientific Officer, Director of Mindset Pharma

Neuroscience 2022 by the Society of Neuroscience
Location: San Diego, CA
Title: “The Preclinical Safety, Behavioural and Pharmacokinetics Properties of MSP-1014, a Novel Prodrug of Psilocin”
Date/Time: Sunday, November 13, 2022, at 8:00 a.m. PT
Presenter: Joseph Araujo, Chief Scientific Officer, Director of Mindset Pharma

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267
​​
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FAQ

What is the significance of the MSP-1014 presentations at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit?

The presentations highlight the preclinical safety, behavioral, and pharmacokinetic properties of MSP-1014, demonstrating its potential as a next-generation treatment.

When will Mindset Pharma present data on MSP-1014?

Mindset Pharma will present data on MSP-1014 on October 31, 2022, at 3:15 p.m. ET in Boston, and again on November 13, 2022, at 8:00 a.m. PT in San Diego.

What topics will be covered regarding MSP-1014 at the conferences?

Topics include the safety, behavioral, and pharmacokinetic properties of MSP-1014 compared to psilocybin, and analyses of psilocybin effects in various animal models.

Who is presenting the MSP-1014 data for Mindset Pharma?

Joseph Araujo, Chief Scientific Officer of Mindset Pharma, will present the data.

What is MSP-1014 and its relevance in drug development?

MSP-1014 is a novel prodrug of psilocin being developed to address neuropsychiatric and neurological disorders with unmet medical needs.